Medidata technology has helped to bring COVID-19 vaccines and treatments to market in record timelines and the company was the first to have launched a fully end-to-end Decentralised Clinical Trials (DCT) offering. Decentralised clinical trials, described as the ‘new normal’ and the future of clinical research, harness remote technologies to enable patients to participate in clinical trials from their home or preferred location, decreasing patient burden and offering greater flexibility as well as increasing the reach to patients around the world. Lisa Moneymaker is the Senior Vice President of Clinical Operations Technologies for Medidata Solutions. She has over 20 years of pharma, biotech, and medical device industry experience, delivering complex systems solutions in support of excellence in clinical trial execution. Paul O’Donohoe is Senior Director, eCOA Product and Science at Medidata. He is responsible for developing the company's scientific expertise for electronic clinical outcome assessments, and mobile health in clinical trials, and supports internal teams and sponsors around the implementation of industry and regulatory best practices in studies using eCOA. Listen to this podcast to find out more about why decentralised clinical trials are becoming increasingly significant, how the pandemic has affected the clinical trials space, the importance of the patient experience and what clinical trials will look like in the future.